“…Studies have shown that VLCFA-LysoPCs, specifically C26:0-LysoPC, is elevated in patients with X-linked adrenoleukodystrophy (X-ALD) and other peroxisomal disorders like Zellweger spectrum disorders (ZSD), acyl CoA oxidase 1 (ACOX1) deficiency, multifunctional protein (HSD17B4) defect and Aicardi Goutieres Syndrome (AGS) [ [5] , [6] , [7] , [8] , [9] , [10] ]. LysoPCs are generally measured by tandem mass spectrometry using the flow injection analysis (FIA-MS/MS) or liquid chromatography-tandem mass spectrometry (LC-MS/MS) techniques for identifying these disorders [ [6] , [7] , [8] , [9] , [10] , [11] , [12] , [13] , [14] , [15] , [16] , [17] , [18] , [19] , [20] , [21] ].…”